EDSA vs HALO vs PFE vs MRK vs JNJ

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Merck & Co. , Inc. (MRK) offers the better valuation at 16. 4x trailing P/E (23. 2x forward), making it the more compelling value choice. Analysts rate Edesa Biotech, Inc. (EDSA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 16. 4x versus Johnson & Johnson at 41. 6x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 37x versus Johnson & Johnson's 37. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +77. 7%, compared to -85. 6% for Edesa Biotech, Inc. (EDSA). Over 10 years, the gap is even starker: HALO returned +701. 6% versus EDSA's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edesa Biotech, Inc.

(EDSA) is the lower-risk stock at -0. 18β versus Halozyme Therapeutics, Inc. 's 0. 58β — meaning HALO is approximately -426% more volatile than EDSA relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Edesa Biotech, Inc. grew EPS 34. 2% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for Edesa Biotech, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for EDSA. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 37x versus Johnson & Johnson's 37. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 6x forward P/E versus 23. 2x for Merck & Co. , Inc. — 14. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HALO: 27. 0% to $88. 25.

In this comparison, PFE (6.

6% yield), MRK (2. 7% yield), JNJ (2. 0% yield) pay a dividend. EDSA, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

01), 2. 0% yield, +142. 4% 10Y return). Both have compounded well over 10 years (JNJ: +142. 4%, HALO: +701. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EDSA is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; PFE is a mid-cap income-oriented stock; MRK is a large-cap deep-value stock; JNJ is a large-cap quality compounder stock. PFE, MRK, JNJ pay a dividend while EDSA, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.